Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients
with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and
preliminary efficacy of the compound
Phase:
Phase 1
Details
Lead Sponsor:
Palobiofarma SL
Collaborator:
Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO)